 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 January 1993 | Volume 118 Issue 2 | Pages 129-138
Objective: To assess the relative effect of different antihypertensive agents on proteinuria and renal function in patients with diabetes.
Data Sources: We used MEDLINE and bibliographies in recent articles to identify studies of the effects of antihypertensive agents on renal function in patients with diabetes.
Study Selection: We selected 100 controlled and uncontrolled studies that provided data on renal function, proteinuria, or both, before and after treatment with an antihypertensive agent.
Data Extraction: Data on blood pressure, renal function, proteinuria, patient characteristics (for example, age, sex, and type of diabetes), and study design (for example, random allocation and the use of a placebo) were extracted from selected studies.
Data Synthesis: Multiple linear regression analysis indicated that angiotensin-converting enzyme (ACE) inhibitors decreased proteinuria independent of changes in blood pressure, treatment duration, and the type of diabetes or stage of nephropathy, as well as study design (P < 0.0001). Reductions in proteinuria from other antihypertensive agents could be entirely explained by changes in blood pressure. Blood pressure reduction in itself was associated with a relative increase in glomerular filtration rate (regression coefficient [±SE], 3.70 ±.92 mL/min for each reduction of 10 mm Hg in mean arterial pressure; P = 0.0002); however, compared with other agents, ACE inhibitors had an additional favorable effect on glomerular filtration rate that was independent of blood pressure changes (3.41 ± 1.71 mL/min; P = 0.05).
Conclusion: Angiotensin-converting enzyme inhibitors can decrease proteinuria and preserve glomerular filtration rate in patients with diabetes. These effects occur independent of changes in systemic blood pressure.
Author and Article Information
From Hennepin County Medical Center, Minneapolis, Minnesota.
REVIEW
Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis
Requests for Reprints: Bertram L. Kasiske, MD, Division of Nephrology, Department of Medicine, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415.
Acknowledgments: The authors thank Ms. Jan Lovick and Ms. Dee Lunzer for help in preparing the manuscript; and Thomas Louis, PhD, Chairman, Department of Biostatistics, University of Minnesota, for helpful suggestions and guidance.
This article has been cited by other articles:
|
|
 |
|
  Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1116 - 1143. [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society Circulation, September 20, 2005; 112(12): 1825 - 1852. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chiurchiu, G. Remuzzi, and P. Ruggenenti Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S58 - S63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Daskalopoulou, D. P. Mikhailidis, and M. Elisaf Prevention and Treatment of the Metabolic Syndrome Angiology, November 1, 2004; 55(6): 589 - 612. [Abstract] [PDF]
|
|
|
|
|
|
S. S. Daskalopoulou, D. P. Mikhailidis, and M. Elisaf Prevention and Treatment of the Metabolic Syndrome Angiology, November 1, 2004; 55(6): 589 - 612. [Abstract] [PDF]
|
|
|
|
 |
|
 G. F M Strippoli, M. Craig, J. J Deeks, F. P. Schena, and J. C Craig Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review BMJ, October 9, 2004; 329(7470): 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Koomans, P. J. Blankestijn, and J. A. Joles Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wiecek, J. Chudek, and F. Kokot Role of angiotensin II in the progression of diabetic nephropathy--therapeutic implications Nephrol. Dial. Transplant., July 1, 2003; 18(90005): v16 - 20. [Full Text] [PDF]
|
|
|
|
|
|
W. M. McClellan and W. D. Flanders Risk Factors for Progressive Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S65 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Flack, R. Peters, T. Shafi, H. Alrefai, S. A. Nasser, and E. Crook Prevention of Hypertension and Its Complications: Theoretical Basis and Guidelines for Treatment J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S92 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Ohmit, J. M. Flack, R. M. Peters, W. W. Brown, and R. Grimm Longitudinal Study of the National Kidney Foundation's (NKF) Kidney Early Evaluation Program (KEEP) J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S117 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Tomlinson, K. R. Owen, and C. F. Close Treating Hypertension in Diabetic Nephropathy Diabetes Care, June 1, 2003; 26(6): 1802 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fournier, O. Godefroy, R. Oprisiu, M. Slama, M. Andrejak, R. S. MacWalter, K. Y.K. Wong, S. Y.S. Wong, A. D. Struthers, and Y. Ersoy Converting Enzyme Inhibitor or AT1-Receptor Blocker for Decreasing Long-Term Mortality in Patients With Stroke History and Renal Dysfunction? Stroke, January 1, 2003; 34(1): 8 - 9. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Treatment of Type 2 Diabetes: The American Association of Clinical Endocrinologists Meeting, May 2002 Diabetes Care, September 1, 2002; 25(9): 1644 - 1649. [Full Text] [PDF]
|
|
|
|
|
|
S. Andersen, P. Rossing, T. R. Juhl, J. Deinum, and H.-H. Parving Optimal dose of losartan for renoprotection in diabetic nephropathy Nephrol. Dial. Transplant., August 1, 2002; 17(8): 1413 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A J Devonald and F. E Karet Targeting the renin-angiotensin system in patients with renal disease J R Soc Med, January 8, 2002; 95(8): 391 - 397. [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Bakris A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients Arch Intern Med, December 10, 2001; 161(22): 2661 - 2667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Suzuki, O. Lopez-Franco, D. Gomez-Garre, N. Tejera, C. Gomez-Guerrero, T. Sugaya, R. Bernal, J. Blanco, L. Ortega, and J. Egido Renal Tubulointerstitial Damage Caused by Persistent Proteinuria Is Attenuated in AT1-Deficient Mice : Role of Endothelin-1 Am. J. Pathol., November 1, 2001; 159(5): 1895 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D Timmis Diabetes: Relationship to ischaemic heart disease Br. Med. Bull., October 1, 2001; 59(1): 159 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Schrier and R. O. Estacio The Effect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease: A Pooled Analysis of Individual-Patient Data from 11 Randomized, Controlled Trials Ann Intern Med, July 17, 2001; 135(2): 138 - 139. [Full Text] [PDF]
|
|
|
|
|
|
M. Bojestig, B. E. Karlberg, T. Lindström, and F. H. Nystrom Reduction of ACE Activity Is Insufficient to Decrease Microalbuminuria in Normotensive Patients With Type 1 Diabetes Diabetes Care, May 1, 2001; 24(5): 919 - 924. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. W. Taal, G. M. Chertow, H. G. Rennke, A. Gurnani, T. Jiang, A. Shahsafaei, J. L. Troy, B. M. Brenner, and H. S. Mackenzie Mechanisms underlying renoprotection during renin-angiotensin system blockade Am J Physiol Renal Physiol, February 1, 2001; 280(2): F343 - F355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Melville, R Richardson, D Lister-Sharp, and A McIntosh Complications of diabetes: renal disease and promotion of self-management Qual. Saf. Health Care, December 1, 2000; 9(4): 257 - 263. [Full Text]
|
|
|
|
|
|
E. Grossman, F. H. Messerli, and U. Goldbourt High Blood Pressure and Diabetes Mellitus: Are All Antihypertensive Drugs Created Equal? Arch Intern Med, September 11, 2000; 160(16): 2447 - 2452. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. M. Wright Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 3: Angiotensin-converting-enzyme inhibitors Can. Med. Assoc. J., August 1, 2000; 163(3): 293 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Grossman, F. H. Messerli, and J. M. Neutel Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors? Arch Intern Med, July 10, 2000; 160(13): 1905 - 1911. [Full Text] [PDF]
|
|
|
|
|
|
P. C. Deedwania Hypertension and Diabetes: New Therapeutic Options Arch Intern Med, June 12, 2000; 160(11): 1585 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Silverstein and A. L. Rosenbloom New Developments in Type 1 (Insulin-Dependent) Diabetes Clinical Pediatrics, May 1, 2000; 39(5): 257 - 266. [Abstract] [PDF]
|
|
|
|
|
|
R. A. Rodby, R. D. Rohde, W. R. Clarke, L. G. Hunsicker, D. A. Anzalone, R. C. Atkins, E. Ritz, and E. J. Lewis The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics Nephrol. Dial. Transplant., April 1, 2000; 15(4): 487 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C R V Tomson Recent advances: Nephrology BMJ, January 8, 2000; 320(7227): 98 - 101. [Full Text]
|
|
|
|
|
|
R. D. Feldman, N. Campbell, P. Larochelle, P. Bolli, E. D. Burgess, S. G. Carruthers, J. S. Floras, R. B. Haynes, G. Honos, F. H.H. Leenen, et al. 1999 Canadian recommendations for the management of hypertension Can. Med. Assoc. J., December 14, 1999; 161(90120): S1 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lurbe and J. Redon Assessing ambulatory blood pressure in renal diseases: facts and concerns Nephrol. Dial. Transplant., November 1, 1999; 14(11): 2564 - 2568. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy, I. J. Benjamin, G. L. Burke, A. Chait, R. H. Eckel, B. V. Howard, W. Mitch, S. C. Smith Jr, and J. R. Sowers Diabetes and Cardiovascular Disease : A Statement for Healthcare Professionals From the American Heart Association Circulation, September 7, 1999; 100(10): 1134 - 1146. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chang, S. Sauereisen, M. Dlutowski, J. J. Veloski, and D. B. Nash A Cost-Effective Method to Characterize Variation in Clinical Practice Eval Health Prof, June 1, 1999; 22(2): 184 - 196. [Abstract] [PDF]
|
|
|
|
|
|
A. L. Peters and W. Hsueh Antihypertensive Agents in Diabetic Patients: Great Benefits, Special Risks Arch Intern Med, March 22, 1999; 159(6): 541 - 542. [Full Text] [PDF]
|
|
|
|
|
|
A. Remuzzi, N. Perico, F. Sangalli, G. Vendramin, M. Moriggi, P. Ruggenenti, and G. Remuzzi ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy Am J Physiol Renal Physiol, March 1, 1999; 276(3): F457 - F466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Remuzzi and T. Bertani Pathophysiology of Progressive Nephropathies N. Engl. J. Med., November 12, 1998; 339(20): 1448 - 1456. [Full Text] [PDF]
|
|
|
|
|
|
M. Rahman and M. C. Smith Chronic Renal Insufficiency: A Diagnostic and Therapeutic Approach Arch Intern Med, September 14, 1998; 158(16): 1743 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 BMJ, September 12, 1998; 317(7160): 713 - 720. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Pfaffendorf Angiotensin-Converting Enzyme Inhibitors an Angiotensin II-Receptor Antagonists Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 222 - 230. [Abstract] [PDF]
|
|
|
|
 |
|
 F. H. Messerli, E. Grossman, and U. Goldbourt Are {beta}-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?: A Systematic Review JAMA, June 17, 1998; 279(23): 1903 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gaster and I. B. Hirsch The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes Arch Intern Med, January 26, 1998; 158(2): 134 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Velasquez, J. S. Striffler, A. A. Abraham, O. E. Michaelis IV, E. Scalbert, and N. Thibault Perindopril Ameliorates Glomerular and Renal Tubulointerstitial Injury in the SHR/N-Corpulent Rat Hypertension, November 1, 1997; 30(5): 1232 - 1237. [Abstract] [Full Text]
|
|
|
|
|
|
J. R. Sowers and M. Epstein Diabetes Mellitus and Associated Hypertension, Vascular Disease, and Nephropathy : An Update Hypertension, December 1, 1995; 26(6): 869 - 879. [Abstract] [Full Text]
|
|
|
|
|
|
E. J. Lewis, L. G. Hunsicker, R. P. Bain, R. D Rohde, and The Collaborative Study Group The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy N. Engl. J. Med., November 11, 1993; 329(20): 1456 - 1462. [Abstract] [Full Text]
|
|
|
|
|
|
G. Remuzzi and P. Ruggenenti Slowing the Progression of Diabetic Nephropathy N. Engl. J. Med., November 11, 1993; 329(20): 1496 - 1497. [Full Text]
|
|
Article
